Adebrelimab before surgery for esophageal cancer: 2 vs 4 cycles
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called Adebrelimab (an immunotherapy) given before surgery to treat esophageal squamous cell cancer. It compares 2 cycles of treatment with 4 cycles to see which works better. The goal is to shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer that is squamous cell type and can be removed with surgery.
- Your cancer is locally advanced (it has spread to nearby lymph nodes but not to distant organs).
- You are between 18 and 75 years old and feel well enough to be up and about (ECOG 0-1).
- You have not had any previous treatment for your esophageal cancer like chemotherapy, radiation, or surgery.
- Your liver, kidney, and blood counts are within normal ranges.
- You do not have an autoimmune disease, active infection, or history of severe allergic reactions to similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
This trial tests whether giving immunotherapy and chemotherapy at a specific time of day improves outcomes for people with esophageal cancer before surgery. It may help shrink the tumor and make surgery more effective.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.